

insight into the risk of bleeding and greater confidence in therapeutic decisions.

The TEG 6s Hemostasis Analyzer System with our PlateletMapping ADP & AA Cartridge provides a comprehensive view of a patient's hemostasis to help assess risk and answer critical questions about your patient's hemostasis:

- How is the patient's platelet function responding to their antiplatelet therapy?
- What is the effect on coagulation?
- What is their risk of bleeding during surgery?
- What is their risk of thrombotic or ischemic events?

When the clinical need arises, the TEG 6s system can also run a Global Hemostasis assay, making it the only cartridge-based viscoelastic testing system offering both global hemostasis and platelet function assessment.





The TEG® 6s PlateletMapping® Cartridge shows underlying hemostasis — including baseline platelet function and receptor-specific platelet function and inhibition.

ONE CARTRIDGE • FOUR ASSAYS • AUTOMATED TEST PREPARATION Personalized patient platelet function analysis Identify underlying Determine Arachidonic Acid Kaolin hemostatic response to Assesses strength imbalance **A**spirin (MA parameter) of clotting. Thrombin Assesses AA stimulated generated TEG provides platelet clot strength and baseline platelet percentage inhibition function, 0% inhibition. relative to baseline. Activator ADP Reference point Determine Activator F Adenosine Diphosphate (ADP) response to ADP for 100% Assesses fibrin only Assesses ADP stimulated platelet inhibition inhibitors clot strength. clot strength and percentage inhibition relative to baseline.

How TEG PlateletMapping works

- A Kaolin activated sample produces a strong thrombin response to maximally activate all platelets and cleave all available fibrinogen demonstrating the underlying potential for maximum clot strength (MAThrombin).
- A second assay blocks all thrombin and uses a special activator to demonstrate the clot strength coming from fibrin (MAA).
- The 3rd and 4th assays also block all thrombin and activate platelets at either the ADP-activated receptor (that thienopyridines like clopidogrel inhibit) or Thromboxane A2 receptor (that aspirin affects), thus demonstrating the clot strength when platelets are activated only through those specific receptors (MAADP or MAAA).
- The degree of inhibition is calculated using the patient's full hemostatic potential as the baseline and contribution of platelets activated through specific receptors, yielding a personalized platelet function analysis.

Ordering Information

Description	Item Code
TEG 6s Hemostasis Analyzer System	07-690-US
PlateletMapping ADP & AA Cartridge (box/10)	07-614-US
Also Available	
PlateletMapping ADP Cartridge (box/10)	07-615-US

To Order

Phone: 800.537.2802, Option 3

Fax: 800.860.1512

Email: customerservicena@haemonetics.com

© 2019 Haemonetics Corporation. Haemonetics and TEG are trademarks or registered trademarks of Haemonetics Corporation in the USA, other countries, or both. All rights reserved. PlateletMapping is a registered trademark of Cora Healthcare, Inc. 09.2019 USA. COL-COPY-001361-US(AA)

For a list of worldwide office locations and contact information, visit www.haemonetics.com/officelocations